What is Annexon's software and technology licenses, net?

Annexon (ANNX) reported software and technology licenses, net of $8.72M in Q1 2026.

How has Annexon's software and technology licenses, net changed year-over-year?

Annexon's software and technology licenses, net increased by 64.5% year-over-year, from $5.3M to $8.72M.

Annexon ANNX Software and Technology Licenses, Net

Software and Technology Licenses, Net at other companies

Regeneron PharmaceuticalsREGN

——

Vor BiopharmaVOR

——

Cullinan Therapeutics, Inc.CGEM

——

Nektar TherapeuticsNKTR

——

AnaptysBio, Inc.ANAB

——

Amylyx Pharmaceuticals, Inc.AMLX

——

Other financials

Income statement

See full

Operating income-$46.1M+19.8%

Net income-$44.1M+18.8%

EPS (diluted)-$0.23+37.8%

Balance sheet

See full

Cash & equivalents$175.2M+80.4%

Total debt$25.4M-10.2%

Total equity$204.5M-16.1%

Total assets$262.9M-13.2%

Cash flow

See full

Operating cash flow-$46.8M+6.5%

CapEx--100%

Free cash flow-$46.8M+6.6%

Valuation

See full

Market cap$868.37M+223%

Enterprise value$718.59M+261%

Returns & leverage

See full

Return on equity-87.6%+42.3pp

Debt / equity0.1×0.0×

Current ratio6.4×-1.6×

Where this comes from

Reported directly by Annexon in its filing.

Tagged under the XBRL concept us-gaap:OtherAssetsNoncurrent.

The official record: Annexon’s 10-Q, filed May 7, 2026, on SEC EDGAR. View the filing →

Ask your AI about Annexon's software and technology licenses, net.

Connect your AI assistant and compare it to peers, right in your chat.

Connect your AI

Claude

Questions, answered.

What is Annexon's software and technology licenses, net?: Annexon (ANNX) reported software and technology licenses, net of $8.72M in Q1 2026.
How has Annexon's software and technology licenses, net changed year-over-year?: Annexon's software and technology licenses, net increased by 64.5% year-over-year, from $5.3M to $8.72M.